Company Overview

Genenta Science S.p.A. is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of cancer. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on oncology. Its core product candidate, Temferon, is designed to reprogram hematopoietic stem cells to deliver immune-modulating proteins directly into the tumor microenvironment, aiming to enhance anti-tumor immune responses while reducing systemic toxicity.

Founded in Italy as a spin-off from academic research institutions, Genenta has evolved from a preclinical research entity into a publicly traded company listed on the Nasdaq under the ticker GNTA. The company’s strategy is centered on leveraging its proprietary ex vivo lentiviral gene therapy platform to address solid tumors with high unmet medical need, positioning itself uniquely at the intersection of cell therapy, gene therapy, and immuno-oncology.

Business Operations

Genenta’s operations are primarily organized around its single operating segment, Gene Therapy Development, which encompasses research, clinical development, and regulatory advancement of its oncology-focused pipeline. The company does not currently generate commercial revenue, as its activities are focused on clinical trials and associated research and development efforts. Its lead program, Temferon, is being evaluated in early-stage clinical trials for indications including glioblastoma and other solid tumors.

Operationally, Genenta conducts research and development through a combination of internal scientific teams and external collaborations with academic institutions, contract research organizations, and manufacturing partners. The company controls proprietary vector design and cell-processing methodologies but relies on third-party manufacturers for certain aspects of clinical-grade production. Data on additional material subsidiaries or revenue-generating joint ventures is inconclusive based on available public sources.

Strategic Position & Investments

Genenta’s strategic direction centers on advancing Temferon through clinical development while validating its broader gene therapy platform for potential expansion into additional oncology indications. Growth initiatives are primarily focused on progressing clinical trials, generating clinical efficacy and safety data, and engaging with regulatory authorities in the United States and Europe. The company has emphasized disciplined capital allocation to support clinical milestones rather than diversification into non-core assets.

The company’s investments are predominantly internal, directed toward research and development rather than acquisitions. Public disclosures do not indicate completed acquisitions of other biotechnology companies, and information regarding equity investments in external portfolio companies is inconclusive based on available public sources. Genenta’s emerging technology focus remains on engineered hematopoietic stem cells and targeted immune modulation within the tumor microenvironment.

Geographic Footprint

Genenta is headquartered in Italy, with its principal executive offices and core research activities located there. The company also maintains a significant operational and regulatory presence in the United States, reflecting its Nasdaq listing, engagement with the U.S. Food and Drug Administration, and execution of U.S.-based clinical trials.

Beyond Europe and North America, Genenta does not report material operational footprints in other regions. Its international influence is primarily through cross-border clinical research activities and collaborations rather than commercial operations or large-scale facilities in additional continents.

Leadership & Governance

Genenta is led by an executive team with experience spanning biotechnology research, clinical development, and capital markets. The leadership emphasizes a strategy grounded in scientific rigor, clinical validation, and regulatory discipline, with a stated focus on translating academic innovation into clinically meaningful therapies for cancer patients.

Key executives include:

• Pierluigi Paracchi – Chief Executive Officer
• Paolo Fiorina – Chief Financial Officer
• Luigi Naldini – Co-Founder and Scientific Advisor
• Giulio Cossu – Co-Founder and Scientific Advisor

The company is governed by a board structure consistent with publicly listed biotechnology companies, with oversight of management, clinical strategy, and shareholder interests.